miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor (Q44077666)

29 November 2017

miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor (English)

1 reference

29 November 2017

0 references

1 reference

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Tobias Kiesslich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Martin Pichler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Elke Winter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Anna Lena Ress

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Thomas Bauernhofer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Armin Gerger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sigurd Lax

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Hellmut Samonigg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

4 October 2013

1 reference

Journal of Clinical Pathology

29 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

198-203

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24098024%20AND%20SRC:MED&resulttype=core&format=json

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

MicroRNA signatures in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

MicroRNAs modulate hematopoietic lineage differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

A deep investigation into the adipogenesis mechanism: profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Prox1 expression is negatively regulated by miR-181 in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Analyzing real-time PCR data by the comparative C(T) method

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Metastatic renal carcinoma comprehensive prognostic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Microribonucleic acids and gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

A common role for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin activity and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201904